TPTX News and Press, Turning Point Therapeutics Inc. From 03/29/22

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Sen...

While maintaining its buy rating, H.C. Wainwright is trimming its price target on Turning Point Therapeutics (TPTX +5.2%) to $161 from $162 (~476% upside based on Monday's close) due to higher operating expenses going forward. Analyst Robert Burns said that following the company's Q4 2021 res...

Enrollment target achieved for expansion cohort 6 (EXP-6) for repotrectinib in NTRK-positive TKI-pretreated advanced solid tumors Company anticipates second repotrectinib pre-NDA meeting in first quarter 2023 to discuss registration timeline for NTRK-positive advanced solid tumor ...

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that due to a conference schedule change, the fireside chat with President ...

Macro concerns dominated Monday's trading, but some big-name stocks still drew attention for individual stories. This included Citigroup (NYSE:C), which lost ground in the wake of an analyst's downgrade. Uber (NYSE:UBER) was also in the spotlight. The stock jumped at the outset of trading on ...

The shares of clinical-stage biotech, Turning Point Therapeutics (NASDAQ:TPTX), is trading ~6% lower on Friday after the precision oncology company announced the resignation of its Executive Vice President and Chief Scientific Officer, Siegfried Reich. On Feb. 28, Dr. Reich informed...

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a fi...

Turning Point Therapeutics press release (NASDAQ:TPTX): Q4 GAAP EPS of -$1.58 misses by $0.21. Cash, Equivalents, and Marketable Securities of approximately $982 Million as of December 31, 2021, Expected to Fund Current Operations into Second Half of 2024. For further details see: Turni...

On Track for TRIDENT-1 ROS1+ NSCLC Topline Data Disclosure and Pre-NDA Meeting Anticipated 2Q 2022 Eighth Regulatory Designation Granted for Repotrectinib with Breakthrough Therapy Designation in China Other Clinical and Preclinical Programs Continue to...

The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech. After the sell-off, biotech companies' valuation is close to the 2018 level even tho...